news

Midatech Pharma awarded EU grant funding to support training and research into glycan based multivalent immunotherapeutics

Posted: 17 December 2014 | Midatech Pharma

Midatech Pharma, a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, is pleased to announce that a consortium of academic and industry groups including Midatech has been awarded a €3.8 million European Union grant…

Midatech Pharma (AIM: MTPH), a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, is pleased to announce that a consortium of academic and industry groups including Midatech has been awarded a €3.8 million European Union grant.

The grant will fund a project entitled “IMMUNOSHAPE” which aims to train a new generation of scientists capable of applying state of the art synthesis and screening technology to develop new lead structures for highly selective glycan based multivalent immunotherapeutics for the treatment of cancer, autoimmune diseases and allergy.

Midatech is applying its glycan coated gold nanoparticle (GNP) technology platform to the treatment of diabetes, a range of orphan oncology indications including brain, liver, pancreatic and ovarian cancer and neurological/ophthalmologic conditions, most of which have multi-$100 million or multi-$billion markets.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

Of the total grant, €227,000 is for Midatech directly, with the balance going to the consortium of nine leading academic groups with expertise in automated solid-phase carbohydrate synthesis, microarray based high-throughput screening technology, tumour immunology, structural glycobiology, multivalent systems and medicinal chemistry along with 4 industrial partners active in nanomedicine, immunotherapy, medicinal device development.

Commenting on the grant award, Dr Jim Philips, CEO of Midatech Pharma, said: “I am pleased that Midatech and its consortium partners have been chosen to receive this grant award from the European Union. The training of new scientists with the skills to develop and apply glycan based immunotherapeutics such as Midatech’s carbohydrate GNP-based treatments for diabetes and cancers will help to ensure these types of improved therapeutics are more rapidly delivered to patients for which there is great medical need.”

Related topics

Related conditions